BioSpace News Archive

Longboard Pharmaceuticals, Inc. today announced that it will host an Investor & Analyst Event focused on the Developmental and Epileptic Encephalopathy (DEE) landscape and LP352, a first-in-class 5-HT2C receptor superagonist in development for the potential treatment of seizures associated with DEEs.

Phytome Life Sciences announces exciting preliminary results from its research collaboration with Inventronics and the University of Plymouth to develop commercial applications for AI-driven technologies in pharmaceutical agriculture.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the T2Biothreat™ Panel.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced two key milestones in its strategic partnership with Illumina Inc., a global leader in DNA sequencing and array-based technologies, to advance and support clinical research for gene-based, targeted therapies.

Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, announced a new partnership with the Benefactors Council of Blue Faery: The Adrienne Wilson Liver Cancer Association, a leading hepatocellular cancer advocacy group.

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company, today announced the full market release of their RevoMotion Reverse Shoulder Arthroplasty System (RSA) at the 2023 Orthopaedic Summit (OSET) Annual Meeting on September 20-23 in Boston, MA.

Icario, the healthcare industry’s leading engagement company, today announced its plans to attend three key industry events in October: HLTH 2023 in Las Vegas, MHPA23 in National Harbor (near Washington, D.C.), and the NCQA Health Innovation Summit in Orlando.

Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) had previously discussed initiation of a series of experiments to validate its DuraCAR CAR-T cell therapeutic.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced that the European, Japan, and Israel Patent Offices have granted the Company a key patent relating to “Compositions comprising an anti-inflammatory drug and a dicer activator for use in treatment of neuronal diseases.”

Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced the successful completion of its 2nd CAR-T NXC-201 engineering batch at its U.S. manufacturing site.